The rift in cancer research
suppose, that the processes usually invoked are, in principle, extremely difficult to observe … and that very similar predictions for the few things we can actually observe may follow from mathematical elaboration of various very different multistage models … Good reasons for a practical person to ignore the broader framing of multistage processes.
However, Peto sees potential for deeper understanding and the benefits that such understanding will bring
No single process is likely to be the whole truth, and we must hope that some grand synthesis of the known processes will eventually be put together which will describe all the essential features of human cancer induction. Although the eventual synthesis is not yet in sight, multistage models should at present be thought about to some extent, and their general features should be common knowledge, as the general framework of this eventual synthesis will … almost certainly be some kind of multistage model.
Followed by a hint of puzzles to come
Moreover, despite all their present uncertainties, multistage models for carcinoma induction have already offered plausible answers to various questions concerning monoclonality, doseresponse relationships under conditions of regular exposure, hypothetical "threshold" doses, the synergistic effects of different carcinogens, the role of luck, and, last but not least, the connection between cancer and aging.
Peto felt strongly about the great insight that might come from asking the right questions. Yet he never forgot that he was running against the crowd. The first two sentences of the article are This section is intended as an introduction to, and apology for, multistage models. Such models occupy a curious position in the world of cancer research.
That conflict is perhaps what gives his article an unusual sense of clarity-of seeing both the great challenges of scientific understanding and the inherent limitations of scientific research. The clarity of these patterns sets a challenge. Any conceptual understanding of cancer must explain these tissue-specific variations.
Many of Peto's specific puzzles build on this basal challenge. His hypothesis is simple.
Cancer is a disease of cell division. The cells of epithelial tissues often divide throughout life, whereas the cells of other tissues typically divide less. That continual renewal of epithelial tissues means a lot of cell division, and thus a lot of cancer. Risk often goes up with a high exponent of the number of cell divisions. Thus, most cancers are late-life carcinomas of epithelial tissues. By contrast, the retina divides early in life and then mostly stops.
Retinoblastoma is rare, and when it occurs, it mostly happens before age five. In bone tissue, much cell division happens during the growth spurt of the teenage years, during which most osteosarcomas occur.
Cell division depends on tissue architecture. In continually renewing epithelial tissues, most cell division occurs in short-lived cell lineages that die out quickly, with little chance of accumulating changes that lead to cancer. The tissue renews from long-lived stem cell lineages that divide rarely. To understand the risk and the timing of cancer, one must understand the nature of cellular renewal. That renewal must be understood in the context of the multiple protections against cancer that ultimately break down before disease progresses.
The outlines of an explanation take shape. The architecture and renewal of a tissue determine the number of divisions in long-lived lineages. The different protections against cancer set the multiple barriers that must be overcome before disease occurs. Peto's final paragraph emphasizes that stochasticity, or luck, plays an essential role
To reach any useful conclusions from these fundamental hypotheses, one has to add extra assumptions … However, all have in common a stochastic approach rather than a deterministic one. Put another way … luck has an essential role … in determining who gets cancer and who does not. The probability of one of my bronchial cells generating a fatal carcinoma can be predicted, but whether in actual fact one cell will do so cannot. Vogelstein is the modern hero because he connected genetics to the mechanisms of change in cells and tissues 10 . This connection opened the way for using the power of genetic technology to get at the biochemical and regulatory changes that happen during cancer progression. It is reasonable to think that only through mechanism can we achieve both an understanding of causality and the potential for control. What came before, including Peto's article, mattered very little as the new prospects for molecular study opened up.
I think that crude summary is mostly right about the history and about cancer research. The new molecular technologies taught us so much, so fast, that it hardly mattered what came before.
But, inevitably, the need to think through what all of the data really mean has once again become a limiting factor. Indeed, the easier it is to obtain great amounts of data, the more one needs to frame the issues in a meaningful way 11 . To get the true modern value of Peto's way of thinking about particular biological problems of cancer, one must first come to some explicit understanding of the intrinsic rift in cancer research that caused Peto to apologize for his approach in his first paragraph. I repeat here the key lines quoted above
It seems likely that multistage processes underlie the generation of a large majority of human
cancers … yet most research workers do not have any real interest in discussing the various alternative multistage models that attempt to describe these processes. These research workers can't all be wrong, so what is wrong with multistage models? The trouble is, I
suppose, that the processes usually invoked are, in principle, extremely difficult to observe … and that very similar predictions for the few things we can actually observe may follow from mathematical elaboration of various very different multistage models … S A FRANK 6
The next section considers the oddness of cancer research from one additional perspective. After that, we will be prepared to consider Peto's discussion of particular puzzles of cancer in relation to modern problems of cancer research. This single factor of immunity seems, by itself, all we need to focus on with respect to both control and causality.
Control versus causality and the nonintuitive scale of risk
The other ! − 1 factors required for cancer are equally powerful for control or for explaining causation. If we focus solely on any single factor, each seems to be nearly sufficient by itself. Of course, everyone knows that cancer requires many changes, and that a single factor alone is not sufficient. Nonetheless, cancer research seemingly fractures into nearly independent subdisciplines, each with its own focal mechanism that holds out the greatest promise for cure and that holds a special place in the causal scheme. 
Peto's puzzles of cancer
This section lists the interesting ideas raised by Peto. The following section analyzes the most important idea for moving current research ahead. That important idea concerns the clear but unexplained pattern by which cancer incidence changes in relation to the dosage, timing, and duration of carcinogen exposure. Currently, the most common approach compares genetically engineered mice or other animals. If a gene causes cancer, then comparing animals with and without a change in that gene should change the incidence of tumors. A change in incidence is usually measured by a significant shift in the overall incidence pattern of tumors, typically by comparison of Kaplan-Meier curves.
There is nothing inherently wrong with such comparative genetic tests. The problem, in the context of Peto's vision, is that the way in which such comparative genetic tests are formulated and analyzed cannot lead to any truly meaningful notion of causality. A meaningful notion of causality tells us how changes in genes or in carcinogenic exposures alter the interaction of multistage rate processes. Those interactions between multistage rate processes together determine the shift in the risk of cancer at each age in response to the changes in the hypothesized causal factor.
That "meaningful notion of causality" is, of course, harder to achieve that a simple genetic manipulation and comparative Kaplan-Meier plot of tumor incidence. But modern technologies combined with both the older carcinogenic tools and Peto's vision for testing hypotheses of causality could achieve the more profound analysis of cause. Such progress would require joining modern work with an older line of thought that has mostly been lost. The following puzzles from Peto recall that older view. 3 , tissues with a stem hierarchy that reduces division in long-lived lineages are more protected against cancer than tissues with a more even distribution of division among cells.
What explains departures from log-log linearity of incidence?
The simplest multistage models predict a linear increase in incidence with age on a log-log plot. The incidence patterns for many epithelial cancers roughly follow log-log linearity, but also tend to depart from pure log-log risk than mice, because humans have so many more cell divisions 13 . Yet the actual rates do not differ greatly. And why don't whales have much more cancer than humans?
One of the most important comments in Peto's article concerns how to approach such apparently inexplicable puzzles
The most direct way to elucidate induction mechanisms for human carcinomas is to study the characteristics of epidemiologically determined causes of human carcinomas, and, in particular, we must look at what happens when a known cause is applied at a different dose rate or for a different time period.
The point is simply that the patterns by themselves will not reveal the underlying processes. Too many different processes lead to the same epidemiological patterns, all consistent with a wide variety of multistage models. To understand why humans get cancers at different rates from mice for a given number of cell divisions, we have to measure how changes in carcinogenic processes alter cancer incidence in humans and in mice. Presumably, humans are less sensitive to carcinogenic processes than are mice. In this context, cell division is itself understood to be an important carcinogenic processes. To understand the differences between humans and mice would mean to understand exactly how the different sensitivities to carcinogenic processes arise.
Note that the ultimate epidemiological pattern of incidence is the only thing that truly matters, because it is the only direct measure of actual cancer cases in relation to an underlying variable, such as cell division or species type. The epidemiological pattern reflects all of the underlying rate processes of cancer progression that interest us. We just have to learn how to read those patterns.
Why does lung cancer incidence level off after cessation of smoking?
Smokers have higher incidence of lung cancer than nonsmokers. The increase in incidence for smokers relative to nonsmokers continues to rise with the number of years of smoking. If a smoker quits, the excess incidence at the age of quitting continues throughout life, but does not change much in the years after quitting. Roughly speaking, the incidence rate levels off after cessation of smoking. Peto comments that this observation is "one of the strongest, and hence most useful, observational restrictions on the formulation of multistage models for lung cancer."
Peto argues that the data are consistent with a simple multistage model in which smoking increases the event rate of the penultimate stage in the development of cancer. The idea is that smoking moves individuals quickly through that penultimate stage to a waiting class just one stage before cancer. The quitters who have moved through that penultimate stage while smoking will have only the final stage remaining before suffering cancer. If they move through that final stage at a constant rate, then incidence per year will be approximately constant after quitting.
This argument for smoking's effect on the penultimate stage of lung cancer progression has been repeated many times 2 .
I think that, for mathematical reasons alone, this is a very weak argument. Many plausible alternative models also fit the data. In spite of the fact that the particular argument is perhaps not so strong, I believe this way of thinking about the relation between variations in carcinogen exposure and incidence does provide the best, and perhaps only, way to connect mechanism to the consequences for outcome-to connect the biochemical and cellular effects of a cause to the ultimate consequence for the appearance of cancer. The conceptual approach is right, but the particular example is not a good one. I return to these issues below.
How do variations in timing and dosage of carcinogen exposure affect the patterns of incidence? Peto discusses changes in lung cancer incidence in relation to the number of cigarettes smoked per day (dosage) and the delay in the age at which smoking starts (timing).
Consider the possible consequences of dosage in terms of multistage progression. If smoking affects only one stage among many in progression, then increasing dose saturates the change in incidence by altering a single normally limiting step into a process that proceeds at such a high rate that it is no longer limiting. At a saturating dose, the incidence curve will trace a higher rate of progression to disease but will have a lower slope with respect to age, because fewer limiting steps remain. In simple multistage theory, the log-log slope is the number of limiting steps minus one. The decrease in log-log slope caused by saturating carcinogen exposure should be roughly equal to the number of stages affected by the carcinogen.
With regard to timing, several aspects may be important. For example, if a carcinogen affects only an early stage in progression, then exposure early in life should have a stronger effect on incidence than exposure late in life. Duration of exposure can also be analyzed in relation to the number of stages affected and the order in which those stages typically limit the development of a tumor.
These ideas about timing, duration, and dosage provide a rich set of hypotheses that can be used to understand comparative studies of subjects with different exposures or to design experimental studies in which these factors are manipulated. For any type of cancer, the predicted response concerns changes in the age-incidence pattern with respect to changes in Peto's article, there was great interest in quantifying the mutagenic effects of chemical agents 15 .
The argument was that the most important carcinogens with respect to risk are typically mutagenic. Peto places this argument about mutagens into the complex observations about how different kinds of chemical agents affect cancer incidence.
To simplify greatly, we might compare mutagens with mitogens. In theory, if one applies a mutagen to initiate cells with mutations, followed by a mitogen that promotes expansion of cellular clones carrying the mutation, then many target cells are present with the risk-bearing mutation, and the effect on incidence should be great. By contrast, if one applies a mitogen first, followed by a mutagen, then the initial clonal expansion does not raise the number of riskbearing mutated cells, and the associated effect on incidence should be small. 
The most important lesson for current research
Peto concludes his summary of carcinogen exposure in relation to cancer incidence by highlighting what he considers to be one of the great unsolved puzzles: that dosage has a much weaker effect than duration of exposure
The fact that the exponent of dose rate is so much lower than the exponent of time is one of the most important observations about the induction of carcinomas, and everyone should be familiar with it-and slightly puzzled by it! Throughout his article, Peto develops a vision of how we should recognize such puzzles, why they are so important for understanding the causes of cancer, and how we should go about analyzing the causes of cancer. His vision is the multistage nature of cancer. Stages are understood as rate processes that define the change in some factor or barrier that must be altered in order for cancer ultimately to arise. Each stage, or cause, can only be understood in relation to how that particular rate process interacts with other processes to determine the overall rate at which cancer develops at each age. The age-incidence curve is the ultimate measure of outcome.
Cause means the way in which a changed input, such as an altered gene or tissue or exposure, changes the output, a shift in the age-incidence curve.
The network of rate processes through which changed inputs shift the age-incidence pattern is too complex to understand intuitively. One must compare a set of clearly formulated hypotheses about the overall multistage process, and use those hypotheses to make specific predictions about the relations between altered inputs and shifts in age-incidence. 
Conclusion
Peto's article expresses great biological insight and mature scientific wisdom. He wrote the article in his early 30s. He followed with one of the brilliant careers in cancer research. His Must it be so? In this era of immense technological power and opportunity for data collection at all scales, perhaps Peto's puzzles will return to inform a deeper understanding.
